Participant has relapsed or refractory multiple myeloma with documented evidence of progression that occurred during or after the participant's last treatment regimen based on investigator's determination of International Myeloma Working Group (IMWG) criteria.
Potential subjects with evidence of progressive disease as per International Myeloma Working Group (IMWG) criteria
Multiple myeloma diagnosed according to the International Myeloma Working Group (IMWG) diagnostic criteria
Diagnosis of MM requiring systemic therapy (per the International Myeloma Working Group [IMWG])
multiple myeloma as per IMWG  definition
Patients with a diagnosis of MM as defined by the  IMWG diagnostic criteria
Diagnosis of relapsed, symptomatic multiple myeloma by International Myeloma Working Group (IMWG) diagnostic criteria for multiple myeloma
Documented initial diagnosis of multiple myeloma according to International Myeloma Working Group (IMWG) diagnostic criteria
Multiple myeloma diagnosis according to the IMWG diagnostic criteria
Diagnosis of multiple myeloma refractory to or relapsed after >=  line of prior therapy (International Myeloma Working Group [IMWG] criteria)
Concurrent multiple myeloma (defined according to  International Myeloma Working Group [IMWG] guidelines)
Must have a confirmed diagnosis of multiple myeloma (MM) requiring therapy according to International Myeloma Working Group (IMWG) criteria.
Documented initial diagnosis of multiple myeloma according to International Myeloma Working Group (IMWG) diagnostic criteria
Diagnosis of symptomatic multiple myeloma as per current International Myeloma Working Group (IMWG) uniform criteria prior to initial treatment
Subjects must have a confirmed prior diagnosis of active MM as defined by the International Myeloma Working Group (IMWG) criteria
Must have a diagnosis of a MM using current International Myeloma Working Group (IMWG) diagnostic criteria and have received  prior line of therapy.
Diagnosis of multiple myeloma as per International Myeloma Working Group (IMWG) uniform criteria
Patient with multiple myeloma relapsing according to the International uniform response criteria for multiple myeloma (IMWG / revised Blad criteria) to one previous line of treatment
Documented diagnosis of multiple myeloma (MM) based on standard IMWG criteria.
Documented diagnosis of symptomatic multiple myeloma, as defined by the IMWG
Patient has been previously diagnosed with multiple myeloma (MM) based on standard International Myeloma Working Group (IMWG) criteria
Diagnosis and previously untreated active multiple myeloma by International Myeloma Working Group (IMWG) diagnostic criteria for multiple myeloma
Evidence of multiple myeloma disease progression (as defined by International Myeloma Working Group [IMWG]) any time prior to ASCT
Diagnosis of MM requiring systemic therapy (per the International Myeloma Working Group [IMWG] ).
Clinically overt multiple myeloma, according to the International Myeloma Working Group (IMWG) criteria with at least  of the following:
Measurable disease on Screening per International Myeloma Working Group (IMWG) criteria.
Patient has been previously diagnosed with multiple myeloma (MM) based on standard criteria and currently requires treatment because MM has relapsed following a response, according to International Myeloma Working Group (IMWG) criteria.
All subjects must have documented disease progression per IMWG criteria during or after their last anti-myeloma therapy.
Participants proven to have multiple myeloma (MM) diagnosis according to the International Myeloma Working Group (IMWG) diagnostic criteria
Patients who at initial diagnosis or later met the International Myeloma Working Group (IMWG) definition of active multiple myeloma requiring therapy (Appendix )
Patients must have histologically or cytologically confirmed smoldering multiple myeloma confirmed by Department of Pathology, based on the International Myeloma Working Group Criteria
Patients with a diagnosis of multiple myeloma (MM) per standard International Myeloma Working Group (IMWG) criteria
Participants must have a diagnosis of multiple myeloma (MM) according Revised International Myeloma Working Group diagnostic criteria:
Note: Laboratory assessments used to support the hypercalcemia, renal failure, anemia, bone lesions (CRAB) criteria in the International Myeloma Working Group (IMWG)  diagnostic criteria of MM are performed at the time of diagnosis; these assessments are not required to be performed within the  days of initiation of protocol therapy
Patients must have a history of symptomatic multiple myeloma according to the International Myeloma Working Group criteria (IMWG, )
Must have documented evidence of progressive disease as defined by the International Myeloma Working Group criteria on or after their last regimen
Participants must have a previous diagnosis of MM, according to International Myeloma Foundation  diagnostic criteria
Newly diagnosed, myeloma requiring systemic chemotherapy as per International Myeloma Working Group (IMWG) uniform criteria:\r\n* Prior treatment of hypercalcemia or spinal cord compression or active and/or aggressively progressing myeloma with corticosteroids or lenalidomide or bortezomib-based regimens does not disqualify the patient (the treatment dose should not exceed the equivalent of  mg of dexamethasone in a  week period or not more than  cycle)\r\n* Bisphosphonates are permitted
Patients must have histologically or cytologically confirmed relapsed multiple myeloma as defined by the International Myeloma Working Group (IMWG)
Diagnosis of active Multiple Myeloma according to the International Myeloma Working Group (IMWG) diagnostic criteria
Histologic and serologic findings from Memorial Sloan-Kettering Cancer Center (MSKCC) confirming the diagnosis of multiple myeloma; standard diagnostic criteria for multiple myeloma will be used, as per the revised International Myeloma Working Group diagnostic criteria
Symptomatic multiple myeloma by International Myeloma Working Group (IMWG) criteria according to the most recent updated version (International Myeloma Workshop [IMW] meeting in Paris )
Must have a documented diagnosis of relapsed and refractory multiple myeloma defined by the International Myeloma Working Group (IMWG) criteria.
Meets the International Myeloma Working Group (IMWG) definition of Multiple Myeloma
Newly diagnosed symptomatic multiple myeloma (per International Myeloma Working Group [IMWG] diagnostic criteria)
Diagnosis of symptomatic MM as defined by the International Myeloma Working Group (IMWG) :
Elevated Free Light Chain as per the International Myeloma Working Group (IMWG) criteria
Patient has relapsed or relapsed/refractory MM with measurable disease parameters according to the International Myeloma Working Group (IMWG) Criteria
Patients must have a definitive diagnosis of multiple myeloma (using the International Myeloma Working Group Guidelines)
Participants must have a diagnosis of relapsed multiple myeloma according to standard criteria established by the International Myeloma Working Group
Multiple myeloma or plasma cell leukemia with a PR or better to the last treatment regimen, based on the International Myeloma Working Group (IMWG) criteria
Diagnosed with multiple myeloma and in complete, partial or very good partial remission at enrollment as per standard International Myeloma Working Group Criteria
Documentation of r/r MM as defined by the International Myeloma Working Group (IMWG) criteria.
Diagnosis of multiple myeloma with documented relapsed or refractory disease according to international Myeloma Working Group (IMWG) criteria, or relapsed/refractory plasma cell leukemia